Pfizer (PFE) Holdings Lifted by Day & Ennis LLC

Day & Ennis LLC boosted its holdings in Pfizer (NYSE:PFE) by 9.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 25,213 shares of the biopharmaceutical company’s stock after purchasing an additional 2,250 shares during the quarter. Day & Ennis LLC’s holdings in Pfizer were worth $913,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of PFE. First Dallas Securities Inc. bought a new position in shares of Pfizer during the 4th quarter valued at approximately $118,000. Americafirst Capital Management LLC bought a new position in shares of Pfizer during the 3rd quarter valued at approximately $127,000. Delphi Private Advisors LLC boosted its position in shares of Pfizer by 84.3% during the 4th quarter. Delphi Private Advisors LLC now owns 3,499 shares of the biopharmaceutical company’s stock valued at $127,000 after acquiring an additional 1,600 shares during the last quarter. Oak Point Wealth Management bought a new position in shares of Pfizer during the 4th quarter valued at approximately $165,000. Finally, Cerebellum GP LLC bought a new stake in Pfizer in the fourth quarter worth $166,000. Institutional investors and hedge funds own 71.65% of the company’s stock.

A number of analysts recently issued reports on the company. Jefferies Group set a $38.00 price target on Pfizer and gave the stock a “hold” rating in a research report on Friday, April 13th. BMO Capital Markets lowered their price target on Pfizer from $43.00 to $42.00 and set an “outperform” rating for the company in a research report on Wednesday, May 2nd. Morgan Stanley raised their price target on Pfizer from $41.00 to $43.00 and gave the stock a “buy” rating in a research report on Wednesday, January 31st. Citigroup restated a “sell” rating on shares of Pfizer in a research report on Thursday, April 12th. Finally, Morningstar set a $43.50 price target on Pfizer and gave the stock a “buy” rating in a research report on Wednesday, May 2nd. Three analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have given a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $40.08.

PFE stock opened at $35.71 on Friday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.98 and a current ratio of 1.27. Pfizer has a twelve month low of $35.64 and a twelve month high of $35.80. The firm has a market capitalization of $212.46 billion, a price-to-earnings ratio of 13.48, a price-to-earnings-growth ratio of 1.77 and a beta of 0.89.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, May 1st. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.03. Pfizer had a return on equity of 25.29% and a net margin of 41.29%. The business had revenue of $12.91 billion for the quarter, compared to analyst estimates of $13.14 billion. During the same quarter last year, the firm posted $0.69 earnings per share. The business’s revenue was up 1.0% compared to the same quarter last year. sell-side analysts predict that Pfizer will post 2.95 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 1st. Shareholders of record on Friday, May 11th will be paid a $0.34 dividend. The ex-dividend date is Thursday, May 10th. This represents a $1.36 dividend on an annualized basis and a yield of 3.81%. Pfizer’s payout ratio is 51.32%.

In other news, insider Kirsten Lund-Jurgensen sold 9,510 shares of the firm’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $37.19, for a total transaction of $353,676.90. Following the transaction, the insider now owns 36,959 shares in the company, valued at $1,374,505.21. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Ian C. Read sold 132,312 shares of the firm’s stock in a transaction on Tuesday, May 1st. The shares were sold at an average price of $36.01, for a total value of $4,764,555.12. The disclosure for this sale can be found here. In the last quarter, insiders sold 380,349 shares of company stock worth $13,829,340. Insiders own 0.06% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply